Exploring the dynamic crosstalk between the immune system and genetics in gastrointestinal stromal tumors

A Dimino, C Brando, L Algeri, V Gristina, E Pedone… - Cancers, 2022 - mdpi.com
Simple Summary The effect of genetic alteration on the prognosis of patients affected by
GIST has been extensively demonstrated. Unfortunately, not all GISTs could benefit from …

Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review

Y Shen, DKH Thng, ALA Wong, TB Toh - Experimental Hematology & …, 2024 - Springer
Glioblastoma (GBM) is a fatal brain tumour that is traditionally diagnosed based on
histological features. Recent molecular profiling studies have reshaped the World Health …

[PDF][PDF] 胃肠间质瘤诊断和治疗进展

林晨, 张再重, 王烈 - 肿瘤防治研究, 2022 - zlfzyj.com
摘要近年来, 随着新研究证据的出现, 胃肠间质瘤(GISTs) 领域的国内外指南随之作出更新,
从GISTs 诊断, 生物学行为, 手术治疗到靶向药物治疗, 几乎涵盖了GISTs 管理的每个环节 …

Locoregional treatments for metastatic gastrointestinal stromal tumor in british columbia: A retrospective cohort study from january 2008 to december 2017

T Patterson, H Li, J Chai, A Debruyns, C Simmons… - Cancers, 2022 - mdpi.com
Simple Summary It is not known if surgery, radiation treatment (RT) or other types of
locolregional treatment (LRT) may be beneficial for patients with metastatic gastrointestinal …

[HTML][HTML] Co-targeting of ACK1 and KIT triggers additive anti-proliferative and-migration effects in imatinib-resistant gastrointestinal stromal tumors

W He, L Xu, J Ding, L Song, W Yang, I Klooster… - … et Biophysica Acta (BBA …, 2023 - Elsevier
Most gastrointestinal stromal tumors (GIST) harbor mutated receptor tyrosine kinase (RTK)
KIT/PDGFRA, which provides an attractive therapeutic target. However, a majority of GISTs …

The identity of PDGFRA D842V-mutant gastrointestinal stromal tumors (GIST)

A Rizzo, MA Pantaleo, A Astolfi, V Indio, M Nannini - Cancers, 2021 - mdpi.com
Simple Summary Among the platelet-derived growth factor receptor (PDGFRA) mutations in
gastrointestinal stromal tumors (GIST), the most frequent is the substitution at position 842 in …

Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation

J Yin, F Zhu, ZB Zhang, Q Wang, XF He, Q Wu… - Annals of …, 2022 - Springer
Chromosomal abnormality t (8; 21)(q22; q22) occurs in about 7% of adult patients with de
novo acute myeloid leukemia (AML)[1]. Although t (8; 21) AML is categorized as a favorable …

Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors

J Du, H Yan, Z Xu, B Yang, Q He… - Expert opinion on drug …, 2021 - Taylor & Francis
ABSTRACT Introduction By 1 January 2021, the FDA has approved a total of 62 small-
molecule kinase inhibitors (SMKIs). The increasing clinical use of small-molecule kinase …

[HTML][HTML] Key genes and drug delivery systems to improve the efficiency of chemotherapy

Z Torres-Martinez, Y Delgado… - Cancer Drug …, 2021 - ncbi.nlm.nih.gov
Cancer cells can develop resistance to anticancer drugs, thereby becoming tolerant to
treatment through different mechanisms. The biological mechanisms leading to the …

[HTML][HTML] Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report

S Huang, X Guo, Y Xia, L Ding, E Zhai… - Annals of …, 2022 - ncbi.nlm.nih.gov
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. Surgery and tyrosine kinase inhibitor (TKI) therapy are the main …